TD Cowen Reiterates Buy Rating on Acelyrin Inc (SLRN)

TD Cowen analyst Tyler Van Buren reiterated a Buy rating on Acelyrin Inc (NASDAQ: SLRN).

The analyst commented, "The lead program, loni for TED, has completed the first three cohorts of the ongoing Phase II study, with the fourth ongoing. Phase II data and Phase III trial design details (EOPII meeting completed) will be shared in Q1, with a Phase III initiating shortly thereafter. A Phase III uveitis readout for izo will come next month, where the goal is for a superior result to Humira."

For an analyst ratings summary and ratings history on Acelyrin Inc click here. For more ratings news on Acelyrin Inc click here.

Shares of Acelyrin Inc closed at $5.98 yesterday.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• AI/ML Innovations plans $2M private placement on the CSE
• Cantor Fitzgerald Reiterates Overweight Rating on Merlin Labs (MRLN)